by U.S. Food and Drug Administration, Center for Drug Evaluation and Research
"Q&A with FDA" provides engaging conversation and discussion about the latest regulatory topics. In this podcast series, FDA’s Division of Drug Information will answer some of the most commonly asked questions received by FDA.
Language
🇺🇲
Publishing Since
7/20/2022
Email Addresses
1 available
Phone Numbers
0 available
December 4, 2024
FDA's Dr. Catherine Gray shares insights on recognizing and reporting false or misleading prescription drug promotion, helping industry professionals stay compliant and protect public health.
October 29, 2024
In this episode of the Q&A with FDA podcast, learn about Understanding Drug Recalls with Dr. Ileana Elder in the Office of Compliance.
September 27, 2024
In this episode of the Q&A with FDA podcast, learn about Utilizing Generic Drug Awareness to Improve Patient Outcomes with Dr. Sarah Ibrahim from FDA’s Office of Generic Drugs.
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.
